Dr. Brufsky on Implementing Pertuzumab in HER2+ Breast Cancer
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, on implementing pertuzumab (Perjeta) in the treatment of patients of HER2-positive breast cancer.
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, on implementing pertuzumab (Perjeta) in the treatment of patients of HER2-positive breast cancer.
Clinicians are still not sure how to best implement pertuzumab into the disease course, says Brufsky. The question is, he says, is extra pertuzumab necessary?
Brufsky says that a lot of clinicians will give upfront neoadjuvant therapy with pertuzumab, and then have to decide about additional doses.
